Inspire Medical Systems (INSP) to Release Earnings on Monday

Inspire Medical Systems (NYSE:INSP) is expected to announce its Q1 2025 earnings results after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $194.89 million for the quarter.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $159.89 on Friday. Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $257.40. The business’s fifty day moving average is $160.65 and its two-hundred day moving average is $179.78. The stock has a market capitalization of $4.76 billion, a P/E ratio of 92.42, a P/E/G ratio of 2.86 and a beta of 1.39.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on INSP shares. Morgan Stanley reduced their target price on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a “hold” rating for the company in a research note on Monday, April 21st. Piper Sandler cut their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. KeyCorp reduced their price target on shares of Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Finally, Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Inspire Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $218.90.

Insider Activity

In related news, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This trade represents a 77.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares of the company’s stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by corporate insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.